ABSTRACT
Background Heart failure (HF) is associated with poor outcomes in persons with chronic kidney disease (CKD), yet there are limited data on whether outcomes differ by HF subtype. This study aimed to examine associations of incident preserved (HFpEF) versus reduced (HFrEF) ejection fraction (EF) with risk of progression to end-stage-kidney-disease (ESKD) and mortality.
Methods We studied individuals with mild to severe CKD enrolled in the Chronic Renal Insufficiency Cohort (CRIC) study who were free of HF at cohort entry. Incident HF hospitalizations were adjudicated during study follow-up and classified into HFpEF (EF>50%) or HFrEF (EF<50%) based on echocardiograms performed during the hospitalization or at a research study visit within one year of the hospitalization. ESKD was defined as need for chronic dialysis or kidney transplant during follow-up. Cox proportional hazards were used to evaluate the association of time-updated HF subtype with risk of ESKD and mortality, adjusting for demographics, comorbidities and medication use.
Results Among the 3,557 study participants without HF at cohort entry, mean age was 57 years and mean eGFR 45 ml/min/1.73 m2 at baseline. Incidence rates for HFpEF and HFrEF were 0.9 (95% CI 0.8, 1.0) and 0.7 (95% CI 0.6, 0.8) per 100 person-years, respectively. Adjusted associations of incident HF with progression to ESKD were similar for HFpEF (HR 1.59, 95% CI: 1.24, 2.02) and HFrEF (HR 1.26, 95% CI: 0.93, 1.70) (test for difference p-value=0.35). The adjusted associations of HFpEF and HFrEF HF with mortality were stronger for HFrEF (HR 1.68, 95% CI: 1.34, 2.11) compared with HFpEF (HR 1.24, 95% CI: 1.00, 1.54) (test for difference p-value = 0.02).
Conclusions In a large U.S. CKD population, the rates of HFpEF hospitalizations were greater than that of HFrEF. Both types of HF had similar associations with risk of ESKD; however, there was a stronger association of HFrEF with mortality. Prevention and treatment of both HFpEF and HFrEF should be central priorities to improve clinical outcomes in patients with CKD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIH
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This used the NIDDK repository data so the parent study received IRB approval from the recruitment sites
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
all data available through NIDDK repository
